报告期内，公司创新产品在巩固国产领先优势的基础上，通过下沉市场、提供定制化治疗方案以及产品 升级迭代，加速推广新品、替换老产品等策略，推动市占率稳步提升，但考虑到2024年市场价格治理因 素影响的延续性，公司部分产品价格及推广策略的调整因素，全年销售额增速及利润仍受到一定影响。 格隆汇2月27日丨心脉医疗(688016.SH)公布2025年年度业绩快报，报告期内，公司实现营业总收入13.51 亿元，同比增长11.96%；归属于母公司所有者的净利润5.63亿元，同比增长12.17%；归属于母公司所有 者的扣除非经常性损益的净利润5.02亿元，同比增长26.97%；基本每股收益4.65元，同比增长14.25%。 报告期内，公司海外销售收入超过2.5亿元，同比增长超过55%，在公司收入占比提升至18%以上，并且 公司持续推动全球范围内与区域行业领先客户的合作，持续推进主动脉及外周介入产品在欧洲、拉美、 亚太等国家的市场准入和推广工作。截至报告期末，公司产品销售覆盖49个国家和地区（含中国）。 ...

证券代码：688016 证券简称：心脉医疗 公告编号：2026-004 二、经营业绩和财务状况情况说明 上海微创心脉医疗科技（集团）股份有限公司 2025 年年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本公告所载2025年年度主要财务数据为初步核算数据，未经会计师事务所审 计，具体数据以公司2025年年度的定期报告为准，提请投资者注意投资风险。 一、2025 年度主要财务数据和指标 单位：元 | 项目 | 本报告期 | 上年同期 | 增减变动幅度 | | --- | --- | --- | --- | | | | | （％） | | 营业总收入 | 1,350,632,689.26 | 1,206,326,728.85 | 11.96% | | 营业利润 | 653,891,743.30 | 661,172,432.85 | -1.10% | | 利润总额 | 653,374,650.83 | 652,193,918.34 | 0.18% | | 归属于母公司所有者的净 利润 | 563,213,12 ...

Core Viewpoint - The company has received regulatory approval for its first embolic product in the tumor intervention field, which is expected to enhance its product pipeline, although actual sales impact remains uncertain until production licenses are obtained [1] Recent Events - A national centralized procurement for 316 commonly used drugs, including those for anti-tumor treatments, has been initiated, with a selection rate of 93%. This may exert price pressure on the pharmaceutical industry, and the company should be aware of the risks associated with high-value consumables procurement expansion [2] Stock Performance - The company's stock price fluctuated between a high of 100.00 yuan and a low of 97.60 yuan over the past week, with a total price change of 1.21% and a volatility of 2.46% [3] Capital Movement - There was a net outflow of 197.72 million yuan in main funds on February 5, with a significant single purchase accounting for 6.03%. The total trading volume over the past week was 619 million yuan, indicating active turnover, while the medical device sector saw a slight decline of 0.48% [4] Financial Report Analysis - For the first three quarters of 2025, the company reported revenue of 1.015 billion yuan, a year-on-year increase of 4.66%, while net profit decreased by 22.46% to 429 million yuan. The gross margin stood at 70.4%, with a significant revenue increase of 64.68% in the third quarter, although net profit was impacted by product price adjustments [5] Financial Condition - The company has a debt ratio of 15.85% and maintains a stable cash flow, with overseas business revenue accounting for 18% of total income in the first three quarters, expected to grow over 60% for the year [6] Institutional Viewpoints - Analysts suggest that while short-term profitability may be under pressure, the company is likely to benefit from innovative product iterations, accelerated overseas expansion, and domestic substitution trends in the medium to long term, with a target price of 122.06 yuan. However, caution is advised regarding procurement policies and potential underperformance in R&D [7]

Core Viewpoint - The stock of Xinmai Medical (688016) has shown a slight increase, with a closing price of 98.3 yuan as of February 9, 2026, indicating a 0.33% rise. The trading volume was 9,421 lots, with a total transaction value of 92.59 million yuan [1]. Financial Performance - For the first three quarters of 2025, Xinmai Medical reported a main revenue of 1.015 billion yuan, reflecting a year-on-year increase of 4.66%. However, the net profit attributable to shareholders decreased by 22.46% to 429 million yuan, and the net profit after deducting non-recurring gains and losses fell by 25.8% to 372 million yuan [1]. - In the third quarter of 2025, the company achieved a single-quarter main revenue of 300 million yuan, which is a significant year-on-year increase of 64.68%. The single-quarter net profit attributable to shareholders was 114 million yuan, down 23.63%, while the net profit after deducting non-recurring gains and losses was 102 million yuan, a decrease of 11.84% [1]. - The company's debt ratio stands at 15.85%, with investment income of 11.6 million yuan and financial expenses of -7.86 million yuan. The gross profit margin is reported at 70.4% [1]. Market Sentiment - Over the last 90 days, three institutions have provided ratings for the stock, all of which are buy ratings [2]. - On February 9, 2026, the net outflow of main funds was 1.7167 million yuan, accounting for 1.85% of the total transaction value. The net outflow of speculative funds was 634,800 yuan, representing 0.69% of the total transaction value, while retail investors saw a net inflow of 2.3515 million yuan, making up 2.54% of the total transaction value [1].

截至2026年2月6日收盘，心脉医疗（688016）报收于97.98元，较上周的95.03元上涨3.1%。本周，心脉 医疗2月5日盘中最高价报99.82元。2月2日盘中最低价报92.17元。心脉医疗当前最新总市值120.77亿 元，在医疗器械板块市值排名27/129，在两市A股市值排名1716/5186。 公司公告汇总 心脉医疗：关于获得医疗器械注册证的自愿性披露公告 近日，上海微创心脉医疗科技（集团）股份有限公司的全资子公司上海拓脉医疗科技有限公司获得国家 药品监督管理局颁发的聚乙烯醇栓塞微球医疗器械注册证，产品适用于富血管型实质性器官恶性肿瘤的 栓塞治疗。该产品为公司肿瘤介入治疗领域首款栓塞类产品，注册证有效期为2026年1月28日至2031年1 月27日。公司另有多个肿瘤介入产品已获批或在研。产品需取得生产许可证后方可上市销售，实际销售 情况受市场推广影响，目前无法预测对公司未来营业收入的影响。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 本周关注点 来自公司公告汇总：心脉医疗全资子公司获聚乙烯醇栓塞微球医疗器械注册证，用 ...

中国国际金融股份有限公司 关于上海微创心脉医疗科技（集团）股份有限公司 2025 年度持续督导工作现场检查报告 根据《证券发行上市保荐业务管理办法》《上海证券交易所上市公司自律监管指引 第11号——持续督导》等有关法律、法规的规定，中国国际金融股份有限公司（以下简 称"保荐机构"、"中金公司"）作为正在履行上海微创心脉医疗科技（集团）股份有 限公司（以下简称"心脉医疗"、"公司"）持续督导工作的保荐机构，对公司2025年 1月1日至2025年12月31日期间（以下简称"本持续督导期间"）的规范运作情况进行了 现场检查，现就现场检查的有关情况报告如下： 一、本次现场检查的基本情况 （一）保荐机构：中国国际金融股份有限公司 （五）现场检查内容：公司治理及内部控制、信息披露、独立性、与关联方的资金 往来、募集资金使用情况、关联交易、对外担保、重大对外投资、公司经营状况等。 （六）现场检查手段:对公司董事会秘书、财务总监等进行访谈；查看公司主要经 营、管理场所；查阅并取得公司公告、公司治理文件、重大合同、公司定期报告等文件； 查阅并取得公司募集资金使用凭证等原始凭证、募集资金专户银行对账单等资料；查阅 公司本持续督导 ...

证券之星消息，截至2026年2月5日收盘，心脉医疗(688016)报收于99.25元，上涨1.66%，换手率 1.82%，成交量2.25万手，成交额2.22亿元。 2月5日的资金流向数据方面，主力资金净流出1082.14万元，占总成交额4.87%，游资资金净流出478.38 万元，占总成交额2.15%，散户资金净流入1560.52万元，占总成交额7.02%。 近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净占比 散户净流入 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2026-02-05 | 99.25 1.66% | | -1082.14万 | -4.87% | -478.38万 | -2.15% | 1560.52万 | 7.02% | | 2026-02-04 | 97.63 1.17% | | 617.84万 | 3.11% | -952.46万 | -4.79% | 334.62万 | 1.68% | | 2026-02-03 | 96.50 4 ...

从基金十大重仓股角度 声明：市场有风险，投资需谨慎。 本文基于第三方数据库自动发布，不代表新浪财经观点，任何在本 文出现的信息均只作为参考，不构成个人投资建议。如有出入请以实际公告为准。如有疑问，请联系 biz@staff.sina.com.cn。 数据显示，新华基金旗下1只基金重仓心脉医疗。新华战略新兴产业灵活配置混合（001294）四季度持 有股数2.47万股，与上期相比持股数量不变，占基金净值比例为4.28%，位居第八大重仓股。根据测 算，今日浮盈赚取约4万元。连续3天上涨期间浮盈赚取17.17万元。 责任编辑：小浪快报 新华战略新兴产业灵活配置混合（001294）成立日期2015年6月29日，最新规模5295.42万。今年以来收 益3.07%，同类排名5393/8873；近一年收益23.33%，同类排名4885/8119；成立以来亏损0.21%。 2月5日，心脉医疗涨1.66%，截至发稿，报99.25元/股，成交2.22亿元，换手率1.82%，总市值122.34亿 元。心脉医疗股价已经连续3天上涨，区间累计涨幅7.53%。 新华战略新兴产业灵活配置混合（001294）基金经理为赖庆鑫。 资料显示，上海 ...

Core Viewpoint - The company Xinmai Medical (688016.SH) announced that its wholly-owned subsidiary, Shanghai Tuomai Medical Technology Co., Ltd. (referred to as "Tuomai Medical"), has received a medical device registration certificate from the National Medical Products Administration for polyvinyl alcohol embolization microspheres, which are intended for the embolization treatment of hypervascular malignant tumors in solid organs [1] Group 1 - The product is specifically designed for the treatment of hypervascular malignant tumors [1] - The registration certificate was issued by the National Medical Products Administration [1] - The product represents a significant advancement in the company's medical device offerings [1]

Group 1 - The core point of the article is that Shanghai MicroPort MedBot (Group) Co., Ltd.'s wholly-owned subsidiary, Shanghai Tuomai Medical Technology Co., Ltd., has received a medical device registration certificate from the National Medical Products Administration for its product "Polyvinyl Alcohol Embolization Microspheres" [1] Group 2 - The product "Polyvinyl Alcohol Embolization Microspheres" is a new medical device aimed at enhancing treatment options in the healthcare sector [1]